Sites of AIDS Clinical Trials Units Announced

The first group of 60 human immunodeficiency (HIV)/AIDS Clinical Trials Units (CTUs) will be carried out by the [U.S.] National Institute of Allergy and Infectious Diseases (NIAID, Bethesda, MD, USA).

These CTUs (and an additional 13 to be named at a later date) have been established to carry out the next generation of HIV/AIDS vaccine, prevention, and treatment research. To this end, NIAID has earmarked US$285 million. This figure includes funding for previously existing CTUs and clinical research sites to continue their participation in ongoing studies for a period to ensure that there are no gaps in current HIV/AIDS research studies. Each CTU will be led by a principal investigator and include an administrative component, community advisory board, and one or more clinical research sites. CTUs will be located in the following US states and territories: Alabama, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Washington DC, and Puerto Rico. Additional CTUs are expected in Louisiana and Washington, D.C.
The CTUs located outside of the US are in the following countries: the Dominican Republic, Haiti, Jamaica, Peru, South Africa and Switzerland. Additional CTUs are anticipated in Brazil, China, France, India, and Thailand.

"These Clinical Trials Units will work with our clinical research networks in a flexible, collaborative, and coordinated way to tackle the critical research questions that can help accelerate progress against the HIV/AIDS pandemic,” said Dr. Anthony S. Fauci, director of NIAID.


Related Links:
National Institute of Allergy and Infectious Diseases